Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Measuring minimal residual disease on day 15 helps identify high-risk leukemia patients.

CD8+ T cells play a key role in graft-versus-host disease in certain mice models.

Dormant melanoma cells in mice interact minimally with memory T cells due to a suppressive tumor environment.

Higher levels of IL-1R1 and hsa-miR-19b-3p may help diagnose and predict alopecia areata severity.

The role of γδT-cells in causing alopecia areata remains unclear.

Super-enhancers control CD25 expression in specific cell types, affecting immune function.

Skin tumors with CYLD cutaneous syndrome show more NF-κB activity and less organized collagen.

BST2 is highly expressed in certain immune cells in alopecia areata, suggesting a role in the disease.

The study suggested certain immune cells might cause alopecia areata, but it was retracted.

CD8 T cells need interferon gamma to cause Alopecia Areata.

The research found that the molecule lncRNA-H19 helps hair follicle cells grow by affecting certain cell pathways in cashmere goats.

COVID-19 vaccination may trigger recurrence of cutaneous T-cell lymphoma in some patients.

10-20% of mouse Tregs have dual TCRs, suggesting potential functional benefits.

CD4 T cells need IFN-γ to cause hair loss in alopecia areata.

The study suggests that a specific type of immune cell, memory-like NK cells, may increase during active hair loss in Alopecia areata.

The number of new cases of cutaneous B-cell lymphoma has leveled off since the early 2000s, and survival rates have improved since 1973.

Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.

Keratin 19 may help diagnose and treat certain types of permanent hair loss.

Blocking certain proteins on immune cells may help treat alopecia areata.

Enhancing Tregs can protect against alopecia areata.

Follicular mycosis fungoides can look like a B-cell lymphoma, making diagnosis difficult.

Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.

Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.

Three characteristics of plasmacytoid dendritic cells help tell apart lupus-related hair loss from LPP.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

IL-17 plays a key role in severe hair loss in chronic alopecia areata.

CK 15, follistatin, and Bmi-1 can help differentiate basal cell carcinoma from squamous cell carcinoma.

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.